Loading
Biomarin Pharmaceutical Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Alles Mark J, was filed 02 Nov 2022.
Insider Decl.
1,331
Thresholds
n/a
Buy Volume
€1M
3 ops. · all time
Sell Volume
€297M
412 ops. · all time
Who traded when
BuySaleCharles Greg Guyer3 sales
Erin Burkhart3 sales
George Eric Davis2 sales
Cristin Hubbard1 sale
Gregory R. Friberg1 sale
Since the insiders bought
- -6.2%Entry US$84.88 · Close at T+365 US$79.59
- +9.2%Entry US$77.99 · Close at T+365 US$85.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Biomarin Pharmaceutical Inc Buy (bullish), based on 27 analysts. Average price target: US$91.56.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,352 of 26,240 companies
56.8
score / 100
Value49
Quality65
FCF yld6.6%
Earn yld3.2%
EV/EBITDA20.1x
ROE1.2%
Gross mgn78%
Net mgn11%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$56.44
Analyst consensus
27 analystsBuy
US$60.00Target US$91.56(+62%)US$122.00
Income statement
RevenueUS$3.2B
Gross profitUS$2.5B78% margin
EBITDAUS$572.9M18% margin
Net incomeUS$348.9M2.1% margin
Valuation
PER (trailing)152.5x
PER (forward)8.8x
P/Book1.7x
Beta0.22
Balance sheet & cash
Market capUS$10.9B
Total debtUS$605.9M
Free Cash FlowUS$717M
Debt / Equity66%
Profitability & ownership
ROE1.2%
ROA3.3%
% insiders0.3%
% institutions103.4%
Last declaration on 1 October 2026
Declarations1,331 total
4,086 shares@ US$60.000.0021% mcap31.2% of flowCommon StockSEC:0001628280-26-064272:0
6,140 shares0Common StockSEC:0001628280-26-061940:0
17,557 shares@ US$66.2840.0098% mcap9.1% of flowCommon StockSEC:0001628280-26-060572:0
7,490 shares0Common StockSEC:0001628280-26-040920:0
7,490 shares0Common StockSEC:0001628280-26-040903:0
7,490 shares0Common StockSEC:0001628280-26-040907:0
7,490 shares0Common StockSEC:0001628280-26-040909:0
7,490 shares0Common StockSEC:0001628280-26-040911:0
7,490 shares0Common StockSEC:0001628280-26-040914:0
7,490 shares0Common StockSEC:0001628280-26-040916:0
7,490 shares0Common StockSEC:0001628280-26-040918:0
7,490 shares0Common StockSEC:0001628280-26-040922:0
2,318 shares@ US$50.200.0009% mcap44.0% of flowCommon StockSEC:0001628280-26-037455:0
1,273 shares@ US$56.050.6% of flowCommon StockSEC:0001628280-26-019862:0
1,693 shares@ US$56.051.8% of flowCommon StockSEC:0001628280-26-019857:0
2,117 shares@ US$56.051.9% of flowCommon StockSEC:0001628280-26-019853:0
4,252 shares@ US$56.0515.2% of flowCommon StockSEC:0001628280-26-019847:0
1,245 shares@ US$56.0520.0% of flowCommon StockSEC:0001628280-26-019269:1
1,629 shares@ US$56.0510.3% of flowCommon StockSEC:0001628280-26-019266:1
15,410 shares0Common StockSEC:0001628280-26-019269:0
19,150 shares0Common StockSEC:0001628280-26-019266:0
62,440 shares0Common StockSEC:0001628280-26-019006:1
14,570 shares0Common StockSEC:0001628280-26-019010:1
14,990 shares0Common StockSEC:0001628280-26-019012:1
18,740 shares0Common StockSEC:0001628280-26-019008:1
25 of 1331 declarations
About Biomarin Pharmaceutical Inc
Henry J. Fuchs (President, Worldwide R&D) made the largest sale at Biomarin Pharmaceutical Inc: EUR 14,338,959 on July 20, 2020, ahead of Jean Jacques Bienaime, then Chief Executive Officer, with EUR 5,769,690 on November 21, 2016 and EUR 5,617,402 the next day. In all, 412 sales worth EUR 296,981,838 (median EUR 354,630), against 3 purchases worth EUR 1,154,966, so purchases are 1% of market trades.
The three purchases are David E. I. Pyott's (Director), EUR 779,644 and EUR 59,432 on August 31, 2020, and Mark J. Alles's (Director), EUR 315,890 on October 31, 2022.
Read moreShow less
This US healthcare and pharma company, valued at USD 10.9 billion and 0.3% held by its insiders, has 1,331 filings published from January 6, 2016 to October 1, 2026, including 591 grants and 284 option exercises. Jean Jacques Bienaime (Director) signed 449, 185 of them sales, ahead of George Eric Davis (EVP, Chief Legal Officer, 132) and Jeffrey Robert Ajer (EVP, Chief Commercial Officer, 118, with 50 sales). Yearly volume peaks at 212 in 2018 and falls to 44 in 2025. The last twelve months hold 45 filings, 4 of them sales and no purchase.
